Trial Profile
Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs MVA 85A (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions
- 07 Feb 2013 Planned number of patients changed from 2784 to 2794.
- 04 Feb 2013 Results published in the Lancet.
- 04 Feb 2013 Results have been reported in an Aeras media release.